Skip to main content
main-content

The independent medical news service

24-06-2020 | Oncology | News | Article

Antiandrogen therapy boosts nonmetastatic CRPC survival

Adding an androgen receptor inhibitor to androgen deprivation therapy significantly improves the overall survival of men with nonmetastatic castration-resistant prostate cancer, according to results from three trials.

11-06-2020 | Oncology | News | Article

CONDOR: 18F-DCFPyL PET diagnoses biochemically recurrent prostate cancer

Positron-emission tomography using the novel prostate-specific membrane antigen targeted 18F-DCFPyL tracer shows “excellent diagnostic performance” in men with biochemically recurrent prostate cancer, researchers report.

02-06-2020 | Oncology | News | Article

Relugolix may offer better testosterone suppression than leuprolide

Men with advanced prostate cancer who receive the gonadotropin-releasing hormone antagonist relugolix are more likely to have sustained suppression of testosterone than those treated with leuprolide acetate, HERO trial data show.

29-05-2020 | Oncology | News | Article

FDA approves rucaparib, olaparib for mutated metastatic CRPC

Read more on these decisions

27-05-2020 | Oncology | News | Article

Data question ADT omission when using EBRT plus brachytherapy boost

Adding androgen deprivation therapy to external beam radiotherapy may result in better survival than adding a brachytherapy boost in men with intermediate- and high-risk prostate cancer, network meta-analysis data suggest.

22-05-2020 | Oncology | News | Article

Data reinforce HSD3B1 variant link to poor mCRPC outcome

Men with metastatic castration-resistant prostate cancer (mCRPC) who carry the CC genotype of the HSD3B1 c.1245A>C variant have worse responses to first-line abiraterone and enzalutamide than those with an AA or AC genotype, research shows.

Image Credits